share_log

Cingulate | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Cingulate | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Cingulate | POS AM：修改注册声明表
美股SEC公告 ·  04/01 17:05

Moomoo AI 已提取核心信息

Cingulate Inc., a biopharmaceutical company based in Delaware, filed a post-effective amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on April 1, 2024. This amendment pertains to the registration of 5,973,000 shares of common stock underlying warrants previously issued in connection with Cingulate's public offering that closed on February 6, 2024. The shares are issuable upon the exercise of pre-funded, Series A, Series B, and placement agent warrants, with exercise prices ranging from $0.0001 to $2.50 per share. The amendment updates financial and other information from the original registration statement, which was declared effective by the SEC on February 2, 2024. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. Cingulate's common stock is listed on the Nasdaq Capital Market under the symbol 'CING', with the last reported sale price on March 28, 2024, being $1.10 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
Cingulate Inc., a biopharmaceutical company based in Delaware, filed a post-effective amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on April 1, 2024. This amendment pertains to the registration of 5,973,000 shares of common stock underlying warrants previously issued in connection with Cingulate's public offering that closed on February 6, 2024. The shares are issuable upon the exercise of pre-funded, Series A, Series B, and placement agent warrants, with exercise prices ranging from $0.0001 to $2.50 per share. The amendment updates financial and other information from the original registration statement, which was declared effective by the SEC on February 2, 2024. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. Cingulate's common stock is listed on the Nasdaq Capital Market under the symbol 'CING', with the last reported sale price on March 28, 2024, being $1.10 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
总部位于特拉华州的生物制药公司Cingulate Inc. 于2024年4月1日向美国证券交易委员会（SEC）提交了其S-1表格注册声明的生效后修正案。该修正案涉及先前发行的与2024年2月6日结束的Cingulate公开发行相关的5,973,000股普通股标的认股权证的注册。这些股票可在行使预先注资、A系列、B系列和配售代理认股权证后发行，行使价从每股0.0001美元到2.50美元不等。该修正案更新了原始注册声明中的财务和其他信息，美国证券交易委员会于2024年2月2日宣布生效。没有根据该修正案注册其他证券，所有适用的注册费均已在最初提交时支付。Cingulate的普通股在纳斯达克资本市场上市，股票代码为 “CING”，上次公布的销售价格为2024年3月28日，为每股1.10美元。该公司被认定为 “新兴成长型公司”，上市公司报告要求有所降低。
总部位于特拉华州的生物制药公司Cingulate Inc. 于2024年4月1日向美国证券交易委员会（SEC）提交了其S-1表格注册声明的生效后修正案。该修正案涉及先前发行的与2024年2月6日结束的Cingulate公开发行相关的5,973,000股普通股标的认股权证的注册。这些股票可在行使预先注资、A系列、B系列和配售代理认股权证后发行，行使价从每股0.0001美元到2.50美元不等。该修正案更新了原始注册声明中的财务和其他信息，美国证券交易委员会于2024年2月2日宣布生效。没有根据该修正案注册其他证券，所有适用的注册费均已在最初提交时支付。Cingulate的普通股在纳斯达克资本市场上市，股票代码为 “CING”，上次公布的销售价格为2024年3月28日，为每股1.10美元。该公司被认定为 “新兴成长型公司”，上市公司报告要求有所降低。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间